BIVI

Biovie Inc

BIVI, USA

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

https://bioviepharma.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BIVI
stock
BIVI

Aug Selloffs: Is Cohu Inc. exposed to currency risks - July 2025 Setups & AI Optimized Trade Strategies baoquankhu1.vn

Read more →
BIVI
stock
BIVI

What Wall Street predicts for BIVI stock price - Weekly Stock Report & Real-Time Stock Entry Alerts bollywoodhelpline.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$12

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.26

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-20.59 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-19.13 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.08

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 2.20% of the total shares of Biovie Inc

1.

Vanguard Group Inc

(0.7123%)

since

2025/03/31

2.

Vanguard Total Stock Mkt Idx Inv

(0.6187%)

since

2025/07/31

3.

Geode Capital Management, LLC

(0.1832%)

since

2025/03/31

4.

Belfund SICAV Belinvest Equity A USD Acc

(0.1327%)

since

2025/07/31

5.

Vanguard Institutional Extnd Mkt Idx Tr

(0.1109%)

since

2025/07/31

6.

Fidelity Extended Market Index

(0.0939%)

since

2025/07/31

7.

UBS Group AG

(0.0661%)

since

2025/03/31

8.

SMH Capital Inc.

(0.0531%)

since

2025/03/31

9.

Fidelity Total Market Index

(0.0319%)

since

2025/07/31

10.

Fidelity Series Total Market Index

(0.0264%)

since

2025/07/31

11.

State Street Corp

(0.0213%)

since

2025/03/31

12.

Traynor Capital Management, Inc

(0.0212%)

since

2025/03/31

13.

Northern Trust Corp

(0.0203%)

since

2025/03/31

14.

Spartan Extended Market Index Pool F

(0.019%)

since

2025/07/31

15.

NT Ext Equity Mkt Idx Fd - L

(0.0188%)

since

2025/06/30

16.

Royal Bank of Canada

(0.015%)

since

2025/03/31

17.

Spartan Total Market Index Pool G

(0.0108%)

since

2025/07/31

18.

Tower Research Capital LLC

(0.0072%)

since

2025/03/31

19.

Morgan Stanley - Brokerage Accounts

(0.0065%)

since

2025/03/31

20.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0053%)

since

2025/06/30

21.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0045%)

since

2024/12/31

22.

SBI Securities Co Ltd

(0.0038%)

since

2025/06/30

23.

Fidelity Nasdaq Composite Index

(0.0031%)

since

2025/07/31

24.

Atlantic Trust Group, LLC

(0.0024%)

since

2025/03/31

25.

Northern Trust Extended Eq Market Idx

(0.0019%)

since

2025/06/30

27.

Spire Wealth Management

(0.0014%)

since

2025/03/31

28.

NT Ext Equity Mkt Idx Fd - NL

(0.0014%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0011%)

since

2025/06/30

30.

JONES FINANCIAL COMPANIES LLLP

(0.0008%)

since

2025/03/31

31.

Advisor Group Holdings, Inc.

(0.0008%)

since

2025/03/31

32.

Vanguard U.S. Eq Idx £ Acc

(0.0008%)

since

2025/07/31

33.

BNYM Mellon SL Market Completion UC1

(0.0004%)

since

2025/06/30

34.

Bank of America Corp

(0.0003%)

since

2025/03/31

35.

Steward Partners Investment Advisory, LLC

(0.0001%)

since

2025/03/31

36.

Tradewinds Capital Management, LLC

(0.0001%)

since

2025/03/31

37.

BlackRock Inc

(0.0001%)

since

2025/03/31

38.

SSgA U.S. Total Market Index Strategy

(0.0001%)

since

2025/03/31

39.

State St US Extended Mkt Indx NL Cl C

(0.0001%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.98

EPS Estimate

-0.79

EPS Difference

-0.19

Surprise Percent

-24.0506%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(2.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Biovie Inc (BIVI) Stock Details & Analysis | Finnton